BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Report in relation to renaming Herzog Park set to be withdrawn - 2A Manual for Nations to Head out To
- 3Releasing Learning Experiences: A Survey of the \Learning Made Fun\ Instructive Application
- 4The 15 Most Motivating TED Discusses All Time
- 5Is an $85 apple pie worth it? Our Thanksgiving taste test says … maybe.
- Which Diet Prompts the Incomparable Wellbeing Results?
- Investigating Inside Plan and Home Style: Change Your Residing Space
- The Way to Recuperation: Defeating Dependence
- Should you get an RSV vaccine this fall? What to know and where to get a shot
- Doggie diversity in size and shape began at least 11,000 years ago
- The 15 Best Business visionaries Under 40
- Which Store is Your Decision ?
- Blue Origin safely launches wheelchair user to space and back
- The most effective method to Explore Moral Situations in Brain research with Your Certification
